Lilly Xu
VP and Head of DMPK & Exploratory Toxicology
biomedicine
ChemPartner
China
Biography
Dr. Lilly Xu, Ph.D. has been Vice President and Head of DMPK & Exploratory Toxicology at Shanghai ChemPartner Company Limited since July 2017. Dr. Xu has more than 20 years of experience in the area of drug metabolism, pharmacokinetics and toxicology. She was one of the pioneers in developing cultured human hepatocytes as a tool to study metabolism of xenobiotics and induction of P450 isozymes. Prior to joining ChemPartner, she served as Head of the Center of Predictive ADMET at Sanofi/Icagen. Dr. Xu holds Ph.D. in Cell and Molecular Biology from Saint Louis University.
Research Interest
Biology
